{"generic":"Technetium Tc 99m Mertiatide","drugs":["Technescan Mag3","Technetium Tc 99m Mertiatide"],"mono":{"0":{"id":"jta7s0","title":"Generic Names","mono":"Technetium Tc 99m Mertiatide"},"1":{"id":"jta7s1","title":"Dosing and Indications","sub":{"0":{"id":"jta7s1b4","title":"Adult Dosing","mono":"<ul><li><b>Measurement of renal function:<\/b> (average 70 kg patient) 185 megabecquerels (5 millicuries) to 370 megabecquerels (10 millicuries) IV<\/li><li><b>Renal isotope studies:<\/b> (average 70 kg patient) 185 megabecquerels (5 millicuries) to 370 megabecquerels (10 millicuries) IV<\/li><\/ul>"},"1":{"id":"jta7s1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy have not been established in infants less than 30 days of age<\/li><li><b>Measurement of renal function:<\/b> (30 days and older) 2.6 megabecquerels\/kg (70 microcuries\/kg) to 5.2 megabecquerels\/kg (140 microcuries\/kg) IV; minimum dose 37 megabecquerels (1 millicurie) IV<\/li><li><b>Renal isotope studies:<\/b> (30 days and older) 2.6 megabecquerels\/kg (70 microcuries\/kg) to 5.2 megabecquerels\/kg (140 microcuries\/kg) IV; minimum dose 37 megabecquerels (1 millicurie) IV<\/li><\/ul>"},"3":{"id":"jta7s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Measurement of renal function<\/li><li>Renal isotope studies<\/li><\/ul>"}}},"3":{"id":"jta7s3","title":"Contraindications\/Warnings","sub":[{"id":"jta7s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jta7s3b10","title":"Precautions","mono":"<ul><li>radiation effects to bladder\/other target organs; encourage patient to increase fluid intake, unless medically contraindicated, and to void often after injection<\/li><li>radiopharmaceutical; maintain adequate shielding of the final preparation and handle with care to reduce radiation exposure to personnel and patient<\/li><\/ul>"},{"id":"jta7s3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"jta7s3b12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk has been demonstrated.<\/li><\/ul>"}]},"5":{"id":"jta7s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Nausea and vomiting<br\/>"},"6":{"id":"jta7s6","title":"Drug Name Info","sub":{"0":{"id":"jta7s6b17","title":"US Trade Names","mono":"Technescan Mag3<br\/>"},"2":{"id":"jta7s6b19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"jta7s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jta7s7","title":"Mechanism Of Action","mono":"The use of technetium Tc 99m mertiatide as a renal imaging agent is based on its clearance through the urinary tract predominantly via active tubular secretion, almost exclusively by the proximal renal tubules,  and to a small extent by glomerular filtration . The rate of appearance and excretion and the concentration of technetium Tc 99m mertiatide in the kidney can be monitored to assess renal function .<br\/>"},"8":{"id":"jta7s8","title":"Pharmacokinetics","sub":{"1":{"id":"jta7s8b24","title":"Distribution","mono":"<ul><li>Protein binding: 89%<\/li><li>Protein binding, renal impairment: 78%<\/li><\/ul>"},"3":{"id":"jta7s8b26","title":"Excretion","mono":"<ul><li>Renal: 90%<\/li><li>Renal, renal impairment: decreased<\/li><li>Hepatobiliary: 3%<\/li><li>Total body clearance: 0.3 L\/min<\/li><li>Total body clearance, renal impairment: decreased<\/li><\/ul>"}}},"9":{"id":"jta7s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>use proper procedures for handling and disposal of radiopharmaceuticals<\/li><li>maintain appropriate shielding throughout the preparation process and for the life of the compound to minimize radiation exposure<\/li><li>wear waterproof gloves during the handling procedure<\/li><li>prepare a water bath with a vial shield and cut openings to allow water circulation though the shield; bring to a continuous rolling boil<\/li><li>place reaction vial in lead dispensing shield fitted with a lid and a wall thickness of at least 1\/8 inch<\/li><li>add 4 to 10 mL (740 megabecquerels (20 millicuries) to 3.7 gigabecquerels (100 millicuries)) of sodium pertechnetate Tc 99m solution to the reaction vial; sodium pertechnetate Tc 99 should not contain oxidizing agents (ie. sodium hypochlorite or hydrogen peroxide)<\/li><li>immediately withdraw syringe to 2 mL to remove 2 mL of argon gas and add 2 mL of filtered air to vial<\/li><li>invert reaction vial several times<\/li><li>transfer reaction vial immediately to water bath inside the lead shield that has equilibrated to the boiling temperature; incubate vial for 10 minutes; vial should be in direct contact with boiling bath and water level should be even with the content of the vial<\/li><li>remove vial, place in lead dispensing shield; allow to cool for 15 minutes<\/li><li>assay reaction vial with a suitable radioactivity calibration system; record date, time, volume, and total technetium Tc 99m activity and concentration on label and affix to lead dispensing shield<\/li><li>use within 6 hours of preparation<\/li><li>check radiochemical purity prior to administration; do not use if less than 90%<\/li><\/ul>"},"10":{"id":"jta7s10","title":"Monitoring","mono":"high quality images of the kidneys are indicative of efficacy<br\/>"},"13":{"id":"jta7s13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, wheezing, dyspnea, itching, rash, tachycardia, shaking chills, fever, or seizure.<\/li><li>Instruct patient to notify their healthcare provider if they are breastfeeding or intend to breastfeed during or around the time of therapy; formula feedings are recommended.<\/li><li>Tell patient to maintain adequate hydration and void frequently during the 6 hours following administration to minimize radiation to the bladder and other target organs.<\/li><\/ul>"}}}